Early Prognostic Factors for Remission Achievement at Etanercept Therapy in Patients with Juvenile Idiopatic Arthritis Without Systematic Manifestations: Prospective Cohort Study

Background. Prognosis of therapy results of patients with the juvenile idiopatic arthritis (JIA) without systematic manifestations is the precondition of their treatment efficiency enhancement.

Objective. Our aim was to establish early predictors for remission achievement in patients with JIA without systematic manifestations who received Etanercept therapy.

Methods. In prospective cohort study the therapy results of patients with JIA without systematic manifestations hospitalized from December, 2009 to August, 2014 and administrated with Etanercept are analysed. The association of initial demographic indicators as well as initial and registered after a month of treatment clinical and laboratory indicators with remission achievement after a year of treatment according to the Wallace criteria is estimated.

Results. The research included 197 patients with JIA without systematic manifestations who received Etanercept in 0.4 mg/kg dose twice a week subcutaneously (the maximum single dose — 25 mg). In addition to Etanercept 136 (69%) patients received Methotrexat, 121 (61%) — non-steroidal anti-inflammatory drugs, 10 (5%) — glucocorticosteroids, 6 (3%) — Sulfasalazine. After a year of treatment remission was recorded in 77 out of 197 (39.1%) patients. According to multivariate analysis the remission predictors are the following: tender joint count 4 (odds ratio (OR) 4.38; 95% confidential interval (CI) 2.33–8.55), duration of illness before Etanercept therapy 2 years (OR 1.28; 95% CI 1.02–2.15), disease activity decline according to JADAS71 index 10 points in a month of the therapy including Etanercept (OR 2.59; 95% CI 1.38–5.03). Model sensitivity was 32% (all three criteria in 25/77 patients with remission), specificity — 94% (lack of even one criteria in 113/120 patients who did not achieve remission).

Conclusion. The predictors of remission in patients with JIA without systematic manifestations in 1 year of Etanercept therapy are smaller tender joint count prior to therapy, smaller duration of illness as well as significant disease activity decline in a month of the therapy. 

1. Giancane G, Alongi A, Ravelli A. Update on the pathogenesis and treatment of juvenile idiopathic arthritis. Curr Opin Rheumatol. 2017;29(5):523–529. doi: 10.1097/BOR.0000000000000417.

2. Yunosheskij artrit. Federal’nye klinicheskie rekomendatsii po vedeniyu patsientov s yunosheskim artritom [Internet]. Moscow: Soyuz pediatrov Rossii; 2017. (In Russ). http://www.pediatr-russia.ru/sites/default/files/file/kr_yua.pdf.

3. van Dijkhuizen EH, Wulffraat NM. Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review. Pediatr Rheumatol Online J. 2014;12:51. doi:10.1186/1546-0096-12-51.

4. Kostik MM, Chikova IA, Isupova EA, et al. Etanercept treatment results in children with nonsystemic juvenile idiopathic arthritis: remission, recrudescence, and adverse events. Retrospective cohort study. Voprosy sovremennoi pediatrici — Current Pediatrics. 2018;17(2):138–147. (In Russ). doi: 10.15690/vsp.v17i2.1880.

5. Vanoni F, Minoia F, Malattia C. Biologics in juvenile idiopathic arthritis: a narrative review. Eur J Pediatr. 2017;176:1147. doi: 10.1007/s00431-017-2960-6.

6. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis.Pediatric rheumatology collaborative study group. N Engl J Med. 2000;342:763–769. doi: 10.1056/NEJM200003163421103.

7. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48(4):1093–1101. doi: 10.1002/art.10885.

8. Davies R, Gaynor D, Hyrich KL, et al. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review. Semin Arthritis Rheum. 2017;46(5):584–593. doi: 10.1016/j.semarthrit.2016.10.008.

9. Geikowski T, Becker I, Horneff G, German BR. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis. Rheumatol (Oxford). 2014;53(7):1245–1249. doi: 10.1093/rheumatology/ket490.

10. Otten MH, Prince FH, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306(21):2340–2347. doi: 10.1001/jama.2011.1671.

11. Alexeeva E, Namazova-Baranova LS, Bzarova T, et al. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the national scientific and practical center of children’s health, Russia. Pediatr Rheumatol Online J. 2017;15:51. doi: 10.1186/s12969-017-0178-9.

12. Solari N, Palmisani E, Consolaro A, et al. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2013;40(2):192–200. oi: 10.3899/jrheum.120842.

13. Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatol (Oxford). 2011;50(1):214–221. doi: 10.1093/rheumatology/keq292.

14. Su Y, Yang YH, Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes. Clin Rheumatol. 2017;36(9):1997–2004. doi: 10.1007/s10067-017-3682-x.

15. Kearsley-Fleet L, Davies R, Lunt M, et al. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatol (Oxford). 2016;55(5): 840–847. doi: 10.1093/rheumatology/kev434.

16. Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:2012–2021. doi: 10.1002/art.34343.

17. Tynjala P, Vahasalo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTEJIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70(9):1605–1612. doi: 10.1136/ard.2010.143347.

18. Hissink Muller PC, Brinkman DM, Schonenberg D, et al. A comparison of three treatment strategies in recent onset non-systemic juvenile idiopathic arthritis: initial 3-months results of the BeSt for Kids-study. Pediatr Rheumatol Online J. 2017;15(1):11. doi: 10.1186/s12969-017-0138-4.

19. Alekseeva EI, Bzarova TM, Valieva SI, et al. Efficacy and safety of etanercept treatment in patients with juvenile idiopathic arthritis without systemic manifestations. The results of an open prospective study on the basis of the scientific center of children’s health (Moscow). Voprosy sovremennoi pediatrici — Current Pediatrics. 2016;15(5): 471–480. (In Russ). doi: 10.15690/vsp.v15i5.1621.

20. Wallace CA, Giannini EH, Huang B, et al.; Childhood Arthritis Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Paediatric Rheumatology International Trials Organisation. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63(7):929–936. doi: 10.1002/acr.20497.

21. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7): 1202–1209. doi: 10.1002/1529-0131(199707)40:73.0.co;2-r.

22. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.

23. Swart JF, van Dijkhuizen EH, Wulffraat NM, de Roock S. Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis. Ann Rheum Dis. 2018;77(3):336–342. doi: 10.1136/annrheumdis-2017-212104.

24. Ringold S, Weiss PF, Beukelman T, et al. 2013 Update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65(10):2499–2512. doi:10.1002/art.38092.

25. Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis. 2012;71: 1437–1439. doi: 10.1136/annrheumdis-2012-201388.

26. Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819–828. doi: 10.1136/annrheumdis-2018-21303.